84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]王笑青,張麗麗,沙莎,等.基于中醫(yī)傳承輔助平臺(tái)挖掘《辨證錄》中痹病內(nèi)服方劑的組方配伍規(guī)律[J].中醫(yī)正骨,2023,35(06):44-48.
　WANG Xiaoqing,ZHANG Lili,SHA Sha,et al.A data mining-based analysis of clinical medication rules of oral prescriptions for treatment of Bi-diseases in Syndrome Differentiation Record using traditional Chinese medicine inheritance support system[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(06):44-48.
點(diǎn)擊復(fù)制

基于中醫(yī)傳承輔助平臺(tái)挖掘《辨證錄》中痹病內(nèi)服方劑的組方配伍規(guī)律()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第35卷
期數(shù):
2023年06期
頁(yè)碼:
44-48
欄目:
文獻(xiàn)研究
出版日期:
2023-06-20

文章信息/Info

Title:
A data mining-based analysis of clinical medication rules of oral prescriptions for treatment of Bi-diseases in Syndrome Differentiation Record using traditional Chinese medicine inheritance support system
作者:
王笑青; 張麗麗; 沙莎; 柳維; 崔亞鴿; 朱久璞; 張永紅
(河南省洛陽(yáng)正骨醫(yī)院/河南省骨科醫(yī)院,河南 洛陽(yáng) 471002)
Author(s):
WANG Xiaoqing; ZHANG Lili; SHA Sha; LIU Wei; CUI Yage; ZHU Jiupu; ZHANG Yonghong
Luoyang Orthopedic-Traumatological Hospital,Luoyang 471002,Henan,China
關(guān)鍵詞:
中醫(yī)藥學(xué)文獻(xiàn);  數(shù)據(jù)挖掘;  方劑構(gòu)成;  組方原則;  聚類(lèi)分析;  痹證;  《辨證錄》
Keywords:
medicine pharmacologic literature(TCM);  data mining;  constitution of formula;  formula composing principles;  cluster analysis;  arthromyodynia;  Syndrome Differentiation Record
摘要:
目的:挖掘《辨證錄》中痹病內(nèi)服方劑的組方配伍規(guī)律。方法:收集《辨證錄》中的痹病內(nèi)服方劑,利用中醫(yī)傳承輔助平臺(tái)(V2.5)對(duì)數(shù)據(jù)進(jìn)行統(tǒng)計(jì)分析,挖掘方劑的組方配伍規(guī)律。結(jié)果:共收集到21首內(nèi)服方劑,涉及65味中藥,其中出現(xiàn)頻次≥3的中藥有20味,排在前5位的分別是白術(shù)、茯苓、肉桂、人參、薏苡仁。21首內(nèi)服方劑的組方藥物中,藥性以溫性出現(xiàn)頻次最多,其次為平性、寒性; 藥味以甘味出現(xiàn)頻次最多,其次為辛味和苦味; 歸經(jīng)以脾經(jīng)出現(xiàn)頻次最多,其次為肺經(jīng)、心經(jīng)、腎經(jīng); 出現(xiàn)頻次≥6的藥物組合有9個(gè),排在前4位的為白術(shù)-茯苓、白術(shù)-肉桂、茯苓-肉桂、白術(shù)-茯苓-肉桂; 核心藥物組合2個(gè),分別為甘草-白術(shù)-干姜、巴戟天-陳皮-薏苡仁。經(jīng)聚類(lèi)分析得到新處方1首,藥物組成為白術(shù)、薏苡仁、陳皮、干姜、巴戟天、甘草。結(jié)論:《辨證錄》中痹病內(nèi)服方劑多采用性溫、味甘、歸脾經(jīng)的藥物; 核心藥物組合以健脾利濕、溫陽(yáng)散寒為主; 以核心藥物組合為基礎(chǔ)聚類(lèi)出的新方,仍符合祛濕溫陽(yáng)的治療大法,可為臨床用藥提供參考,但其療效有待進(jìn)一步研究。
Abstract:
Objective:To excavate the clinical medication rules of oral prescriptions for treatment of Bi-diseases in Syndrome Differentiation Record.Methods:The oral prescriptions aimed at treating Bi-diseases were extracted from the Syndrome Differentiation Record and were statistically analyzed by using traditional Chinese medicine inheritance support system(TCMISS)software(V2.5)for excavating the clinical medication rules.Results:Twenty-one oral prescriptions were included in the final analysis,involving 65 Chinese herbs,among which 20 ones displayed a occurrence frequency of≥3,and the top 5 ones with high occurrence frequency included Atractylodis Macrocephalae Rhizoma,Poria(TCD),Cinnamomi Cortex,Ginseng Radix et Rhizoma and Coicis Semen in turn.Among the 21 oral prescriptions,the most frequently used Chinese herbs were those with a warm property,followed by the ones with a neutral property and a cold property,and the ones with sweet flavors were more preferred,followed by pungent and bitter flavors; and they mainly acted on the spleen meridians,followed by lung meridians,heart meridians and kidney meridians in turn.The occurrence frequency were≥6 in 9 herb combinations,and the top 4 ones with high occurrence frequency included Atractylodis Macrocephalae Rhizoma-Poria(TCD),Atractylodis Macrocephalae Rhizoma-Cinnamomi Cortex,Poria(TCD)-Cinnamomi Cortex and Atractylodis Macrocephalae Rhizoma-Poria(TCD)-Cinnamomi Cortex.The cluster analysis on all the included Chinese herbs generated 2 core herb combinations,namely Glycyrrhizae Radix et Rhizoma(TCD)-Atractylodis Macrocephalae Rhizoma-Zingiberis Rhizoma and Morindae Officinalis Radix-Citri Reticulatae Pericarpium-Coicis Semen,and 1 new prescription were dug out,and its ingredients included Atractylodis Macrocephalae Rhizoma,Coicis Semen,Citri Reticulatae Pericarpium,Zingiberis Rhizoma,Morindae Officinalis Radix and Glycyrrhizae Radix et Rhizoma(TCD).Conclusion:The Chinese herbs are often the ones presented with warm property and sweet flavor and mainly act on spleen meridians in the oral prescriptions aimed at treating Bi-diseases in Syndrome Differentiation Record,and the core herb combinations are mainly the ones for invigorating spleen and eliminating dampness as well as warming Yang and dispelling cold.The new prescription clustered based on core herb combinations conforms to the formula composing principle of dispelling dampness and warming Yang.It can provide references for clinical medication,while their curative effects need to be further studied.

參考文獻(xiàn)/References:

[1] 陳士鐸.辨證錄[M].北京:中國(guó)中醫(yī)藥出版社,2007.
[2] 國(guó)家藥典委員會(huì).中華人民共和國(guó)藥典:一部[M].北京:中國(guó)醫(yī)藥科技出版社,2020.
[3] 吳承洛.中國(guó)度量衡史[M].北京:商務(wù)印書(shū)館,1998:103.
[4] 國(guó)家中醫(yī)藥管理局.中華本草[M].上海:上海科學(xué)技術(shù)出版社,1999.
[5] 南京中醫(yī)藥大學(xué).中藥大辭典[M].上海:上海科學(xué)技術(shù)出版社,2006.
[6] 熊永輝.基于醫(yī)籍文獻(xiàn)人用歷史的痹病用藥規(guī)律挖掘[J].醫(yī)學(xué)理論與實(shí)踐,2022,35(20):3431-3435.
[7] 張曉娟,左冬冬.白術(shù)化學(xué)成分及藥理作用研究新進(jìn)展[J].中醫(yī)藥信息,2018,35(6):101-106.
[8] LIN Z,LIU Y F,QU Y,et al.Characterisation of oligosaeeharides from Baizhu by HILIC-MS[J].Nat Prod Res,2015,29(13):1194-1200.
[9] KWAK T K,JANG H S,LEE M G,et al.Effect of orally administered atractyledes macrocephala koidz water extract on macrophage and T cell inflammatory response in mice[J].Evid Based Complement Altemat Med,2018,2018:4041873.
[10] FAN W,ZHANG S,HAO P,et al.Structure characterization of three polysaccharides and a comparative study of their immunomedulatory activities on chicken macmphage[J].Carbohydr Polym,2016,153:631-640.
[11] LIU Y,ZHANG B,CAI Q.Study on the pharmacodynamics and metabolomics of five medicinal species in Atractylodes DC. on rats with rheumatoid arthritis[J].Biomed Pharmacother,2020,131:110554.
[12] 劉忠第,姜淼,譚勇,等.《臨證指南醫(yī)案》治療痹證的用藥規(guī)律和特色分析[J].中華中醫(yī)藥雜志,2016,31(2):405-409.
[13] 崔鶴蓉,王睿林,郭文博,等.茯苓的化學(xué)成分、藥理作用及臨床應(yīng)用研究進(jìn)展[J].西北藥學(xué)雜志,2019,34(5):694-700.
[14] TIAN H,LIU Z J,PU Y W,et al. Immunomodulatory effects exerted by Poria cocos polysaccharides via TLR4/TRAF6/NF- κB signaling in vitro and in vivo[J].Biomedicine & Pharmacotherapy,2019,112:108709.
[15] 馬艷春,范楚晨,馮天甜,等.茯苓的化學(xué)成分和藥理作用研究進(jìn)展[J].中醫(yī)藥學(xué)報(bào),2021,49(12):108-111.
[16] 張倩,張冰,金銳,等.肉桂油與肉桂水提物對(duì)虛寒證模型大鼠的藥理作用及其數(shù)理分析[J].中西醫(yī)結(jié)合學(xué)報(bào),2011,9(9):983-990.
[17] 王超楠,趙大慶,王隸書(shū),等.人參及復(fù)方人參制劑免疫雙向調(diào)節(jié)機(jī)制及應(yīng)用研究進(jìn)展[J].時(shí)珍國(guó)醫(yī)國(guó)藥,2021,32(1):177-180.
[18] ZHANG C,XU W,CHEN J,et al.Soybean oil containing ginseng saponins as adjuvants promotes production of cytokines and enhances immune responses to foot- and-mouth disease vaccine[J].Microbiol Immunol,2018,62(3):187.
[19] 李曉凱,顧坤,梁慕文,等.薏苡仁化學(xué)成分及藥理作用研究進(jìn)展[J].中草藥,2020,51(21):5645-5657.
[20] 于培明,田智勇,林桂濤.甘味藥的藥性理論及其配伍探討[J].時(shí)珍國(guó)醫(yī)國(guó)藥,2005,16(1):77-78.
[21] 周楊,朱紅梅.辛味藥研究現(xiàn)狀與思考[J].中華中醫(yī)藥雜志,2013,28(6):1647-1650.
[22] 左黎黎,張家瑋.胡希恕與馮世綸六經(jīng)方證辨證治療痹證探頤[J].中華中醫(yī)藥雜志,2017,32(6):2525-2529.
[23] 汪婭蓓,汪悅.《醫(yī)宗必讀》治痹特色探析[J].江蘇中醫(yī)藥,2022,54(4):9-11.
[24] 段麗云,顧成娟.仝小林運(yùn)用茯苓、生白術(shù)、澤瀉利脾濕經(jīng)驗(yàn)[J].吉林中醫(yī)藥,2021,41(1):25-27.
[25] 劉旎.桂枝、肉桂利尿作用及其運(yùn)用規(guī)律的文獻(xiàn)研究[D].北京:北京中醫(yī)藥大學(xué),2019.
[26] 付建武,楊明,鐘凌云,等.參苓白術(shù)散中薏苡仁炮制品種的考證[J].現(xiàn)代中藥研究與實(shí)踐,2021,35(5):91-94.

相似文獻(xiàn)/References:

[1]李剛,程春生.股骨頭壞死血瘀證癥狀與平樂(lè)郭氏正骨方藥藥物組成 最大頻繁關(guān)聯(lián)模式挖掘[J].中醫(yī)正骨,2015,27(04):21.
　LI Gang,CHENG Chunsheng.Maximal frequent association pattern mining for studying the relationship between BLOOD STASIS syndrome in patients with osteonecrosis of femoral head and drug components of Pingle Guo's orthopedics prescription[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):21.
[2]林潔,范展彪,劉獻(xiàn)祥.基于數(shù)據(jù)挖掘技術(shù)探討陳可冀《清宮配方集成》中治療骨關(guān)節(jié)炎組方的用藥規(guī)律[J].中醫(yī)正骨,2017,29(11):15.
　LIN Jie,FAN Zhanbiao,LIU Xianxiang.Study on medication rule extracted from prescription for treatment of osteoarthritis in Royal Formulary of Qing Dynasty written by Chen Keji based on data mining techniques[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(06):15.
[3]楊波,袁普衛(wèi),康武林,等.基于數(shù)據(jù)挖掘法探討李堪印教授治療強(qiáng)直性脊柱炎的用藥規(guī)律[J].中醫(yī)正骨,2020,32(11):74.
[4]李文浩,牛逸群,譚明生.基于數(shù)據(jù)挖掘法探討中醫(yī)藥治療脊髓型頸椎病的用藥規(guī)律[J].中醫(yī)正骨,2021,33(01):22.
　LI Wenhao,NIU Yiqun,TAN Mingsheng.A study of medication rule of Traditional Chinese Medicine for treatment of cervical spondylotic myelopathy based on data mining approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):22.
[5]顧勇,趙艷明,童培建,等.基于數(shù)據(jù)挖掘法探討中藥復(fù)方治療股骨頭壞死的組方規(guī)律[J].中醫(yī)正骨,2021,33(06):49.
　GU Yong,ZHAO Yanming,TONG Peijian,et al.A study of medication rule of Traditional Chinese Medicine compounds for treatment of osteonecrosis of femoral head based on data mining approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):49.
[6]張亞運(yùn),許金海,莫文.基于數(shù)據(jù)挖掘法分析腰椎椎管狹窄癥中藥外用方的用藥規(guī)律[J].中醫(yī)正骨,2021,33(08):28.
　ZHANG Yayun,XU Jinhai,MO Wen.Medication rules of external-applied Chinese herbal medicine prescriptions for treatment of lumbar spinal stenosis:a data mining-based analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):28.
[7]趙睿晞,王人彥.張玉柱教授治療腰椎間盤(pán)突出癥的用藥規(guī)律分析[J].中醫(yī)正骨,2021,33(08):39.
　ZHAO Ruixi,WANG Renyan.An analysis of clinical medication rules of Professor ZHANG Yuzhu in treatment of lumbar disc herniation[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):39.
[8]張杰,丁權(quán)威,張玉柱,等.基于數(shù)據(jù)挖掘法探討張玉柱教授治療神經(jīng)根型頸椎病的辨證用藥規(guī)律[J].中醫(yī)正骨,2021,33(11):41.
　ZHANG Jie,DING Quanwei,ZHANG Yuzhu,et al.Clinical medication rules of Professor ZHANG Yuzhu in treatment of nerve-root type cervical spondylosis based on syndrome differentiation principles:a data mining-based study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):41.
[9]左世國(guó),李姣姣,向昱陽(yáng).《醫(yī)宗金鑒·正骨心法要旨》中骨傷外治處方的用藥規(guī)律分析[J].中醫(yī)正骨,2022,34(02):40.
　ZUO Shiguo,LI Jiaojiao,XIANG Yuyang.Clinical medication rules of the prescriptions for external treatment of orthopedic and traumatic diseases in Yizong Jinjian,Essentials of Bone Orthopedics[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(06):40.
[10]祁建華,明洪,張會(huì)擇,等.基于數(shù)據(jù)挖掘法探討《世醫(yī)得效方》中治傷方劑的用藥規(guī)律[J].中醫(yī)正骨,2022,34(03):20.
　QI Jianhua,MING Hong,ZHANG Huize,et al.A data mining-based analysis of clinical medication rules of prescriptions for treatment of orthopedic and traumatic diseases in Shiyi Dexiao Fang[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(06):20.
[11]徐道情,黃維琛,歐梁,等.基于中醫(yī)傳承輔助平臺(tái)挖掘《正體類(lèi)要》中治傷內(nèi)服方劑的用藥規(guī)律[J].中醫(yī)正骨,2021,33(12):14.
　XU Daoqing,HUANG Weichen,OU Liang,et al.A data mining-based analysis of clinical medication rules of oral prescriptions for treatment of orthopedic and traumatic diseases in Classification and Treatment of Traumatic Diseases using traditional Chinese medicine inheritance support system[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):14.
[12]黃明翥,周紅海,何心愉,等.《醫(yī)宗金鑒·正骨心法要旨》中治療傷科瘀腫疼痛方劑的用藥規(guī)律分析[J].中醫(yī)正骨,2023,35(10):37.
　HUANG Mingzhu,ZHOU Honghai,HE Xinyu,et al.A data mining-based analysis of clinical medication rules of traumatologic prescriptions for treatment of blood stasis,swelling and pain in Yizong Jinjian,Essentials of Bone Orthopedics[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(06):37.
[13]李琰,尹煜輝,劉寧,等.《永類(lèi)鈐方》中骨傷內(nèi)服藥方的用藥規(guī)律分析[J].中醫(yī)正骨,2024,36(04):47.
　LI Yan,YIN Yuhui,LIU Ning,et al.Clinical medication rules of the oral prescriptions for treatment of orthopedic traumatologic diseases(TCM)in Yonglei Qianfang[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(06):47.

備注/Memo

備注/Memo:
通訊作者:張永紅 E-mail:[email protected]
更新日期/Last Update: 1900-01-01